Trials / Unknown
UnknownNCT00363831
Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma
A Multi-center Phase II Trial of Capecitabine in Combination With Oxaliplatin (Xelox) as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NPC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Primary: * To evaluate the efficacy of capecitabine in combination with oxaliplatin (XELOX) in terms of overall response rate (based on RECIST criteria) in patients with metastatic NPC without prior chemotherapy for relapse. Secondary: * To evaluate the efficacy profile of oxaliplatin (XELOX) in patients with metastatic NPC in terms of time to progression of disease, survival time, duration of response and complete response rate. * To study the safety and tolerability of the regimen in patients with metastatic NPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxaliplatin | 130mg/m² infusion day 1, repeat every 21 days |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2009-12-01
- First posted
- 2006-08-15
- Last updated
- 2010-07-28
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT00363831. Inclusion in this directory is not an endorsement.